Alkem Laboratories Limited

“Alkem's domestic branded-generics franchise is a genuine compounder — 20% ROCE, durable MR-driven doctor relationships, and long runway in an underpenetrated Indian market — but the US generics segment suppresses consolidated margins and returns, management has shown no credible intent to restructure it, and the stock at 27x earnings leaves no margin of safety for new buyers. The base case delivers roughly 11–12% annualized returns, which is fair compensation for a holder but insufficient for a fresh entry. The primary permanent-impairment risk (INN generic prescribing mandate) is low-probability but structurally severe. A 15–20% price correction to the INR 4,500–4,700 range would make this a clear buy; at current levels, discipline requires waiting.”